Skip to Main Content

Paper Details

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Oxidized Lipoprotein Levels: A Case Report.
J Appl Lab Med
2
2020
Author NameAffiliation
Naoki SakaneClinical Research Institute, National Hospital Organization Kyoto Medical Center
  • 1 - 1

Datasets

Release 1.2